Workflow
JOINN(603127)
icon
Search documents
港股医药股走强,药明康德涨9.52%、药明合联涨7.19%、昭衍新药涨6.78%、基石药业-B涨5.81%。
news flash· 2025-07-11 01:46
港股医药股走强,药明康德涨9.52%、药明合联涨7.19%、昭衍新药涨6.78%、基石药业-B涨5.81%。 ...
7月10日CRO上涨0.66%,板块个股百诚医药、和元生物涨幅居前
Jin Rong Jie· 2025-07-10 09:49
Group 1 - The CRO sector experienced a slight increase of 0.66% with a total capital inflow of 84.32 million [1] - A total of 27 stocks within the sector saw gains, while 11 stocks experienced declines [1] - The top declining stocks included Yaokang Bio (-3.64%), Zhaoyan New Drug (-2.68%), and Meidi West (-2.04%) [1] Group 2 - Notable stocks with significant capital inflow included Baicheng Pharmaceutical with a price of 48.06 and a rise of 6.05% [1] - Other stocks with positive performance included Heyuan Bio (+4.39%) and Jinkai Biotechnology (+2.76%) [1] - The stock with the highest capital outflow was Yao Stone Technology, which saw a decrease of 8.88% [1]
A股大医药概念早盘震荡走高,CRO、重组蛋白、创新药等概念涨幅居前;美迪西涨超16%,毕得医药涨超7%,昭衍新药、阳光诺和、诺思格等个股跟涨。国家发改委表示,“十四五”以来,402种药品新增进入国家医保药品目录。
news flash· 2025-07-09 03:09
Group 1 - The A-share pharmaceutical sector experienced a strong upward trend in early trading, with significant gains in concepts such as CRO, recombinant proteins, and innovative drugs [1] - Companies like Medisi saw an increase of over 16%, while Bid Pharma rose more than 7%, with other stocks like Zhaoyan New Drug, Sunshine Nuohuo, and Nossger also following suit [1] - The National Development and Reform Commission announced that since the 14th Five-Year Plan, 402 new drugs have been added to the national medical insurance drug list [1]
港股创新药板块持续拉升,昭衍新药涨超8%
news flash· 2025-07-09 02:40
港股创新药板块持续拉升,昭衍新药(603127)涨超8%,绿叶制药涨超7%,泰格医药(300347)、君 实生物、中国生物制药跟涨。 ...
医药生物行业资金流出榜:常山药业等10股净流出资金超亿元
300318 博晖创新 6.37 5.19 3220.45 沪指7月8日上涨0.70%,申万所属行业中,今日上涨的有29个,涨幅居前的行业为通信、电力设备,涨 幅分别为2.89%、2.30%。医药生物行业今日上涨0.31%。跌幅居前的行业为公用事业、银行,跌幅分别 为0.37%、0.24%。 资金面上看,两市主力资金全天净流入154.50亿元,今日有14个行业主力资金净流入,电子行业主力资 金净流入规模居首,该行业今日上涨2.27%,全天净流入资金74.37亿元,其次是电力设备行业,日涨幅 为2.30%,净流入资金为36.78亿元。 主力资金净流出的行业有17个,公用事业行业主力资金净流出规模居首,全天净流出资金22.97亿元, 其次是医药生物行业,净流出资金为22.85亿元,净流出资金较多的还有国防军工、银行、商贸零售等 行业。 医药生物行业今日上涨0.31%,全天主力资金净流出22.85亿元,该行业所属的个股共474只,今日上涨 的有337只,涨停的有6只;下跌的有123只,跌停的有1只。以资金流向数据进行统计,该行业资金净流 入的个股有191只,其中,净流入资金超亿元的有5只,净流入资金居首的是昭衍新药 ...
港股创新药板块继续走强,荣昌生物涨超7%
news flash· 2025-07-08 01:39
Group 1 - The Hong Kong stock market's innovative drug sector continues to strengthen, with Rongchang Biologics rising over 7% [1] - Junshi Biosciences increased by more than 4% [1] - Tigermed (300347) and Zhaoyan New Drug (603127) both saw gains of over 3% [1] Group 2 - Innovent Biologics and Kanglong Chemical (300759) experienced increases of over 2% [1]
港股CXO概念股震荡走低,药明生物跌超5%
news flash· 2025-07-07 03:30
Group 1 - The Hong Kong CXO concept stocks experienced a decline, with WuXi Biologics falling over 5% [1] - Kingsoft Biotech dropped more than 3% [1] - Other companies such as Kelaiying (002821), WuXi AppTec (603259), Tigermed (300347), and Zhaoyan New Drug (603127) saw declines of over 2% [1]
每周股票复盘:昭衍新药(603127)参与投资设立基金及股本情况更新
Sou Hu Cai Jing· 2025-07-05 18:05
Group 1 - The stock price of Zhaoyan New Drug (603127) increased by 16.95% this week, closing at 22.36 yuan, with a weekly high of 22.76 yuan and a low of 18.92 yuan [1] - Zhaoyan New Drug's current total market capitalization is 16.758 billion yuan, ranking 9th in the medical services sector and 950th among all A-shares [1] Group 2 - Zhaoyan New Drug announced its plan to invest up to 20 million yuan in the Huaxia Zhiyuan Venture Capital Fund, which has a target fundraising scale of 35 million yuan [2][4] - The fund will focus on equity investments in unlisted companies related to molecular diagnostics and targeted therapy, with a management fee of 1% per year based on the total capital contributions [2] - As of June 30, 2025, the legal registered capital of Zhaoyan New Drug's H-shares and A-shares remains unchanged at 118,995,206 shares and 630,482,128 shares, respectively [3][4]
昭衍新药: H股公告:6月月报表
Zheng Quan Zhi Xing· 2025-07-04 16:12
| FF301 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | | | | | | | | 截至月份: 2025年6月30日 | | | | | | | | 狀態: 新提交 | | 致:香港交易及結算所有限公司 | | | | | | | | | | 公司名稱: 北京昭衍新藥研究中心股份有限公司 | | | | | | | | | | 呈交日期: 2025年7月4日 | | | | | | | | | | I. 法定/註冊股本變動 | | | | | | | | | | (如上市) 06127 證券代號 說明 | | | | | | | | | | 法定/註冊股份數目 | | | | 面值 | | | | 法定/ | | 註冊股本 | | | | | | | | | | 上月底結存 118,995,206 RMB | | | | | | 1 | | | | RMB 118,995,206 | | | | | | | ...
昭衍新药(603127) - H股公告:6月月报表
2025-07-04 09:00
股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年6月30日 狀態: 新提交 致:香港交易及結算所有限公司 公司名稱: 北京昭衍新藥研究中心股份有限公司 呈交日期: 2025年7月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06127 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 118,995,206 | RMB | | 1 | RMB | | 118,995,206 | | 2. 股份分類 ...